Health
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
REDWOOD CITY, Calif., April 21, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2026 American Society of Clinical Oncology (ASC
About this update from Corcept Therapeutics Incorporated
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":207,"url":"https://media.zenfs.com/en/business-wire.com/411acef8afdfab953beeb5c75b4ab9ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GKdec0c8uulbeU7bTLZmPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQxNA--/https://media.zenfs.com/en/business-wire.com/411acef8afdfab953beeb5c75b4ab9ba","width":480,"height":207}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., April 21, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data will be presented in an oral presentation on Friday, May 29, 2026.","length":611,"tagName":"p"},{"type":"text","content":"Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)","length":274,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Oral Abstract Session – Gynecologic Cancer","length":42,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"May 29, 2026, 2:45 PM – 5:45 PM CDT","length":35,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Abstract Number: 5503","length":21,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":98,"olType":false},{"type":"text","content":"Lifyorli, in combination with nab-paclitaxel, was approved by the U.S. Food and Drug Administration (FDA) in March 2026 for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA). It is included in th...